Miv Investments Inc. has initiated an independent bullish technical trading alert for 11/23/09 on CytRx Corporation (NASDAQ:CYTR). Shares of the company finished trading during 11/20/09 at $1.35 per share, up 20.18% from the opening bell on heavy buying pressure. As of 11/18/09, the biopharmaceutical company announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.[More...]

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

The accompanying table profiles the 13 companies mentioned in this article and statistics for all 113 companies (click here for a link to the entire index) with market caps between $25M-$150M, which are included in the new ETF Innovators (ETFI) Micro-Cap Bio-Pharma Index as a complement to the ETFI Emerging Bio-Pharma Index of companies with market caps between $150M-$1.5B.<br[More...]

Though we're anywhere but in a high growth market presently, there are groups that may provide big upsides based on growth potential, especially in light of major recent pull-backs. One industry that interests us is biotech, so Zacks senior analyst Jason Napodano, CFA helped us with some notable suggestions in the space. What's new in the world of biopharmaceuticals these days? Arena Pharmaceuticals (ARNA) reported financial results for the third quarter 2008. Although results were largely in-line with expectations, investors are starting to take notice of Arena's cash position. Despite the $212.1 million still on the books at the end of September 2008, management has reduced its year-end[More...]

In 2009 first quarter, Toyota Motor Corp. (TM) reported diluted earnings per ADR of $2.14 compared to $2.94 in the corresponding quarter of the previous year. Net revenues decreased 4.7% year over year to $5.92 billion. The company attributes the decrease in revenues to soaring raw material prices and exchange rates fluctuations. Consolidated vehicle sales for the quarter amounted to 2.19 million units, an increase of 24,000 units compared with the same period of fiscal 2008. The company continues to expand its production capacity in a manner that increases efficiency and meets local demand and simultaneously powering it to emerge as the world?s financially strongest automaker. A strong presence in North America has been further consolidated by gaining market share from the leading U.S. automakers. Moreover, the company also has a strong cash flow and a[More...]